Laura Vitali-Serdoz

Dr. Laura Vitali-Serdoz

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Pharmacological Research
Verified
Journal Article
Closed access
Laura Vitali-SerdozLaura Vitali-Serdoz
Laura Vitali-Serdoz
HRHarald Rittger
Harald Rittger
FFFrancesco Furlanello
Francesco Furlanello
DBDirk Bastian
Dirk Bastian

18 May 2019
Verified
Book Chapter
Open access
PDF file
MZMassimo Zecchin
Massimo Zecchin
DMDaniele Muser
Daniele Muser
Laura Vitali-SerdozLaura Vitali-Serdoz
Laura Vitali-Serdoz
ABAlessandra Buiatti
Alessandra Buiatti
TMTullio Morgera
Tullio Morgera
In patients with dilated cardiomyopathy (DCM), it is possible to find a broad range of bradyrhythmias and tachyarrhythmias. Bradyrhythmias and supraventricular arrhythmias can frequently occur in some familial forms such as lamin A/C mutations. Nonsustained ventricular arrhythmias (VA) are observed in about 40% of patients with DCM, but their prognostic role is not clear, and conflicting data have been published in the last 30 years. Multiple mechanisms can explain atrial and ventricular tachyarrhythmias in DCM. Reentry is associated with slow conduction across surviving muscle bundles within regions of interstitial fibrosis, but other mechanisms can be involved, as nonuniform anisotropy of impulse propagation, ion channel dysfunction, and reduced gap junction function. Sudden death (SD) rate has been definitely reduced in the last three decades, but identification of patients at high risk is still a major issue. Despite its limitations, left ventricular (LV) dysfunction is still pivotal for the identification of patients who should be treated with ICD according to current guidelines, while the role of all other invasive and noninvasive parameters is still debated. Cardiac magnetic resonance and possibly genetic analysis, despite not widely available, can be helpful at least in selected cases. Arrhythmias can be the consequence, but also the cause of DCM, in the presence of a sustained heart rate >100/min, after exclusion of other causes of heart failure and if there is a recovery of LV function after achieving arrhythmia control. Finally, pharmacological and non-pharmacological treatment of arrhythmias (in particular ablation) and the role of ICD are discussed.

1 November 2021 in The American Journal of Cardiology
Verified
Journal Article
Closed access
PDF file
DZDenise Zaffalon
Denise Zaffalon
LPLinda Pagura
Linda Pagura
ACAntonio Cannata
Antonio Cannata
GBGiulia Barbati
Giulia Barbati
CGCaterina Gregorio
Caterina Gregorio
GSGianfranco Sinagra
Gianfranco Sinagra

14 December 2021 in Sensors
Verified
Journal Article
Open access
PDF file
ANAlexander Niedermeier
Alexander Niedermeier
Laura Vitali-SerdozLaura Vitali-Serdoz
Laura Vitali-Serdoz
Theodor FischleinTheodor Fischlein
Theodor Fischlein
WKWolfgang Kirste
Wolfgang Kirste
VBVeronica Buia
Veronica Buia
DBDirk Bastian
Dirk Bastian
Background: ICDs and pacemakers for cardiac resynchronization therapy (CRT) are complex devices with different sensors and automatic algorithms implanted in patients with advanced cardiac diseases. Data on the perioperative management and outcome of CRT carriers undergoing surgery unrelated to the device are scarce. Methods: Data from 198 CRT device carriers (100 with active rate responsive sensor) were evaluated regarding perioperative adverse (device-related) events (A(D)E) and lead parameter changes. Results: Thirty-nine adverse observations were documented in 180 patients during preoperative interrogation, which were most often related to the left-ventricular lead and requiring intervention/reprogramming in 22 cases (12%). Anesthesia-related events occurred in 69 patients. There was no ADE for non-cardiac surgery and in pacemaker-dependent patients not programmed to an asynchronous pacing mode. Post-operative device interrogation showed significant lead parameter changes in 64/179 patients (36%) requiring reprogramming in 29 cases (16%). Conclusion: The left-ventricular pacing lead represents the most vulnerable system component. Comprehensive pre and post-interventional device interrogation is mandatory to ensure proper system function. The type of ICD function suspension has no impact on each patient’s outcome. Precautionary activity sensor deactivation is not required for non-cardiac interventions. Routine prophylactic device reprogramming to asynchronous pacing appears inessential. Most of the CRT pacemakers do not require surgery-related reprogramming.

4 March 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DBDirk Bastian
Dirk Bastian
CGCaterina Gregorio
Caterina Gregorio
VBVeronica Buia
Veronica Buia
JWJanusch Walaschek
Janusch Walaschek
HRHarald Rittger
Harald Rittger
Laura Vitali-SerdozLaura Vitali-Serdoz
Laura Vitali-Serdoz
Pace mapping and visual comparison of the local pacing response with the intrinsic QRS morphology form the mainstay of His bundle pacing (HBP). We evaluated the performance of a surface lead morphology match algorithm for automated classification of the pacing response in patients with narrow intrinsic QRS undergoing electroanatomic mapping (EAM)-guided HBP. HBP was attempted in 43 patients. In 28 cases with narrow QRS, the EnSite AutoMap Module was used for automated assessment of the QRS morphology resulting from pace mapping in the His cloud area with either a diagnostic catheter or the His lead. An intrinsic morphology match score (IMS) was calculated for 1.546 QRS complexes and assessed regarding its accuracy and performance in classifying the individual pacing response as either selective HBP (S-HBP), nonselective HBP (NS-HBP) or right ventricular stimulation. Automated morphology comparison of 354 intrinsic beats with the individual reference determined a test accuracy of 99% (95% CI 98.96–99.04) and a precision of 97.99–99.5%. For His-lead stimulation, an IMS ≥ 89% identified S-HBP with a sensitivity, specificity and positive predictive value of 1.00 (0.99, 1.00) and a negative predictive value of 0.99 (0.98, 1.00). An IMS between 78 and < 89% indicated NS-HBP with a sensitivity and specificity of 1.00 (0.99, 1.00) and 0.99 (0.98, 1.00), respectively. IMS represents a new automated measure for standardized individual morphology classification in patients with normal QRS undergoing EAM-guided HBP.Clinical trial registration: NCT04416958.

2 May 2020 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
DBDirk Bastian
Dirk Bastian
VBVeronica Buia
Veronica Buia
JWJanusch Walaschek
Janusch Walaschek
EQEugenio De Quattro
Eugenio De Quattro
HRHarald Rittger
Harald Rittger
Laura Vitali-SerdozLaura Vitali-Serdoz
Laura Vitali-Serdoz